glp 1 kidney Glucagon-like peptide-1 receptor agonists in diabetic disease: A review of their kidney and heart protection GLP-1 receptor agonists and next-generation
Description
The Lemme lawsuit joins a growing number of legal challenges targeting supplement companies for overstated health claims
However, cardiovascular outcomes are still widely debated and controversially evidenced
Access the complete GLP-1 Pipeline Update table for August 2025
The FDA has approved oral semaglutide for adults with obesity (BMI 30) or overweight adults (BMI 27) who also have at least one weight-related condition, such as: Type 2 diabetes High blood pressure Dyslipidemia Cardiovascular disease risk Dr
on Dec 26, 2025 This post may contain affiliate links
However, semaglutide has a longer track record and more safety data in broader populations
